186 filings
Page 4 of 10
6-K
IMAB
I-Mab
4 Mar 22
I-Mab Receives FDA Orphan Drug Designation for its Novel Claudin 18.2 x 4-1BB Bispecific
6:11am
6-K
IMAB
I-Mab
22 Feb 22
Current report (foreign)
4:04pm
SC 13G/A
GIC Private Ltd
14 Feb 22
I-Mab / GIC Private ownership change
9:10am
SC 13G
IMAB
I-Mab
14 Feb 22
I-Mab / PRICE T ROWE ASSOCIATES ownership change
2:34pm
SC 13G/A
Jingwu Zhang Zang
11 Feb 22
I-Mab / Zang Jingwu Zhang ownership change
4:02pm
6-K
IMAB
I-Mab
28 Jan 22
I-Mab’s Announcement on Unusual Price Movement
7:23am
SC 13G/A
CBC Investment I-Mab Ltd
25 Jan 22
I-Mab / CBC Investment I-Mab ownership change
6:40am
424B3
IMAB
I-Mab
14 Jan 22
Prospectus supplement
4:02pm
6-K
IMAB
I-Mab
21 Dec 21
I-Mab Strengthens Management Team Designed to Accelerate Global Pipeline Development and Transformation Towards Commercialization
6:05am
6-K
IMAB
I-Mab
15 Dec 21
I-Mab Presents Interim Clinical Data of Lemzoparlimab in Combination with Rituximab in Relapsed and Refractory Non-Hodgkin Lymphoma at ASH 2021
6:03am
6-K
IMAB
I-Mab
10 Dec 21
Current report (foreign)
4:02pm
6-K
IMAB
I-Mab
8 Dec 21
I-Mab to Pursue Dual Listing Plan on The Main Board of The Stock Exchange of Hong Kong Limited
6:08am
6-K
IMAB
I-Mab
6 Dec 21
Current report (foreign)
6:06am
424B3
IMAB
I-Mab
26 Nov 21
Prospectus supplement
4:02pm
424B3
IMAB
I-Mab
12 Nov 21
Prospectus supplement
4:31pm
6-K
IMAB
I-Mab
12 Nov 21
Index to Consolidated Financial Statements
4:02pm
6-K
IMAB
I-Mab
12 Nov 21
I-Mab and ABL Bio Report Preclinical Data of 4-1BB-targeting Bispecific Antibodies at 2021 SITC
6:15am
6-K
IMAB
I-Mab
5 Nov 21
I-Mab to Present Clinical Data of Lemzoparlimab in Combination with Rituximab
6:07am
6-K
IMAB
I-Mab
2 Nov 21
I-Mab Strengthens Senior Executive Team with New Chief Financial Officer and Chief Strategy
6:07am
6-K
IMAB
I-Mab
19 Oct 21
I-Mab Announces IND Approval for Phase 2 Clinical Trial of Efineptakin Alfa in Combination with PD-1 Therapy in China
4:02pm